225 related articles for article (PubMed ID: 21231986)
1. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
[TBL] [Abstract][Full Text] [Related]
2. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
3. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
[TBL] [Abstract][Full Text] [Related]
5. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
[TBL] [Abstract][Full Text] [Related]
6. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
7. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.
Anderson H; Hills M; Zabaglo L; A'hern R; Leary AF; Haynes BP; Smith IE; Dowsett M
Ann Oncol; 2011 Aug; 22(8):1770-6. PubMed ID: 21285137
[TBL] [Abstract][Full Text] [Related]
8. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
Endo Y; Toyama T; Takahashi S; Sugiura H; Yoshimoto N; Iwasa M; Kobayashi S; Fujii Y; Yamashita H
Int J Clin Oncol; 2011 Oct; 16(5):512-8. PubMed ID: 21431343
[TBL] [Abstract][Full Text] [Related]
9. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.
Kurozumi S; Yamaguchi Y; Matsumoto H; Kurosumi M; Hayashi SI; Fujii T; Horiguchi J; Shirabe K; Inoue K
PLoS One; 2019; 14(5):e0217279. PubMed ID: 31112577
[TBL] [Abstract][Full Text] [Related]
10. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
11. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
[TBL] [Abstract][Full Text] [Related]
12. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Mlineritsch B; Tausch C; Singer C; Luschin-Ebengreuth G; Jakesz R; Ploner F; Stierer M; Melbinger E; Menzel C; Urbania A; Fridrik M; Steger G; Wohlmuth P; Gnant M; Greil R;
Breast Cancer Res Treat; 2008 Nov; 112(1):203-13. PubMed ID: 18158620
[TBL] [Abstract][Full Text] [Related]
13. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.
Tubiana-Hulin M; Becette V; Bieche I; Mauriac L; Romieu G; Bibeau F; Macgrogan G; Bourgeois H; Chollet P; Defrance R; Spyratos F
Anticancer Res; 2007; 27(4C):2689-96. PubMed ID: 17695434
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitors: cellular and molecular effects.
Miller WR; Anderson TJ; White S; Larionov A; Murray J; Evans D; Krause A; Dixon JM
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):83-9. PubMed ID: 16002280
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
Takei H; Kurosumi M; Yoshida T; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Oba H; Inoue K; Nagai S; Tabei T
Breast Cancer; 2011 Apr; 18(2):85-91. PubMed ID: 21104350
[TBL] [Abstract][Full Text] [Related]
17. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Lustberg MB; Povoski SP; Zhao W; Ziegler RM; Sugimoto Y; Ruppert AS; Lehman AM; Shiels DR; Mrozek E; Ramaswamy B; Layman RM; Brueggemeier RW; Shapiro CL
Clin Breast Cancer; 2011 Aug; 11(4):221-7. PubMed ID: 21729671
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
Bartlett JM; Brookes CL; Robson T; van de Velde CJ; Billingham LJ; Campbell FM; Grant M; Hasenburg A; Hille ET; Kay C; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix L; Seynaeve C; Rea D
J Clin Oncol; 2011 Apr; 29(12):1531-8. PubMed ID: 21422407
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Rocca A; Farolfi A; Maltoni R; Carretta E; Melegari E; Ferrario C; Cecconetto L; Sarti S; Schirone A; Fedeli A; Andreis D; Pietri E; Ibrahim T; Montalto E; Amadori D
Breast Cancer Res Treat; 2015 Jul; 152(1):57-65. PubMed ID: 26012644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
